Key Highlights

  • CDNA shares are trading up 17.29% today to $44.69, up from a prior close of $38.10.
  • The gain extends Thursday's 7.60% rally following Q2 results that topped consensus, with revenue up 52% year-over-year to $132 million.
  • Management raised full-year 2026 revenue guidance to $490-500 million and adjusted EBITDA guidance to $66-78 million.
  • A finalized Medicare Local Coverage Determination for the company's AlloSure and AlloMap transplant tests removed a key reimbursement overhang.

Momentum Builds on Medicare Coverage Clarity

CareDx, Inc. (NASDAQ:CDNA) shares are extending their rally today, building on Thursday's surge after the company posted blowout second-quarter 2026 results, with revenue jumping 52% year-over-year to $132 million, well above the $113.8 million consensus, and adjusted EPS of $0.37 crushing the $0.23 estimate. CareDx, known as 'The Transplant Company' and headquartered in Brisbane, California, is a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers.

Growth was driven by 61% growth in Testing Services volume, with management sharply raising full-year 2026 revenue guidance to $490-500 million and adjusted EBITDA guidance to $66-78 million. The rally is also being reinforced by a recently finalized Medicare Local Coverage Determination covering surveillance testing for kidney, heart and lung transplant patients using the company's flagship dd-cfDNA and gene expression tests, including AlloSure and AlloMap, removing a key reimbursement overhang that had previously weighed on shares.

Portfolio Expansion and Valuation Considerations

CareDx carries a market capitalization of approximately $2.31 billion, with shares trading at a trailing price-to-earnings ratio of 53.20. The stock's 52-week range spans $11.26 to $44.84.

The company completed its acquisition of NavDx, a specialty oncology solid tumor MRD platform, on July 1, with integration focused on leveraging CareDx's commercial capabilities and revenue cycle management, and specialty oncology volumes expected to grow 30% year-over-year in the third and fourth quarters. Management also cited the completed sale of its Lab Products business and the closed Naveris acquisition as contributing factors to the raised guidance.

Some analysts have flagged the stock's premium valuation, with a price-to-sales ratio near 4.9 times, as elevated relative to diagnostics peers such as Veracyte and Guardant Health, which also reported strong quarterly results this week. Shares have now rallied sharply this month on Medicare reimbursement clarity, with pipeline progress including AlloHeme, a cell therapy recurrence monitoring test advancing toward a planned 2027 commercial launch.

Conclusion

CareDx's continued rally reflects durable momentum from both a genuine earnings beat and the removal of Medicare reimbursement uncertainty that had weighed on the stock, though the premium valuation now attached to shares raises the bar for continued outperformance. With specialty oncology expansion via NavDx and pipeline programs like AlloHeme progressing toward commercial launch, investors will be watching whether the company can sustain this growth trajectory into 2027.

This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.